Camurus AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1991-01-01
- Employees
- 213
- Market Cap
- -
- Website
- http://www.camurus.com
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
- Conditions
- Polycystic Liver Disease
- Interventions
- Drug: CAM2029Drug: Placebo
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 71
- Registration Number
- NCT05281328
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The New York Presbyterian Hospital, New York, New York, United States
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 332
- Registration Number
- NCT05050942
- Locations
- 🇺🇸
UCLA Ahmanson Biological Imaging Center, Santa Monica, California, United States
🇺🇸Texas Oncology - Dallas, Dallas, Texas, United States
🇺🇸White Plains Hospital - Center for Cancer Care, White Plains, New York, United States
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
- Conditions
- Acromegaly
- Interventions
- Drug: CAM2029 (octreotide subcutaneous depot)
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 135
- Registration Number
- NCT04125836
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸UCLA Department of Medicine Division of Endocrinology, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
- Conditions
- Acromegaly
- Interventions
- Drug: CAM2029 (octreotide subcutaneous depot)Drug: Matching placebo
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 72
- Registration Number
- NCT04076462
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Washington University in St. Louis, School of Medicine, Saint Louis, Missouri, United States
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
- Conditions
- Neuroendocrine TumorsAcromegaly
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 12
- Registration Number
- NCT02299089
- Locations
- 🇫🇷
CHU Rouen, Hôpital Charles Nicolle, Rouen cedex, France
🇩🇪Abteilung: Klinische Studien, Bad Berka, Germany
🇸🇪Akademiska sjukhuset, Uppsala, Sweden
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 51
- Registration Number
- NCT02212197
- Locations
- 🇫🇮
Docrates Cancer Center, Helsinki, Finland
🇭🇺Semmelweis University Hospital Department of Urology, Budapest, Hungary
🇫🇮University Hospital of Helsinki, Department of Urology, Helsinki, Finland
A Comparative Investigation of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral Mucositis
- Conditions
- Oral Mucositis
- Interventions
- Device: episil(R)Other: Oral hygiene procedures
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 116
- Registration Number
- NCT01684566
- Locations
- 🇸🇪
Karin Garming-Legert, Stockholm, Huddinge, Sweden
🇸🇪Lund University Hospital, Lund, Sweden
🇸🇪Uppsala University Hospital, Uppsala, Sweden
Effects of Mucoprotective Product on Xerostomia
- Conditions
- Xerostomia
- Interventions
- Other: XER2020
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 20
- Registration Number
- NCT01316393
- Locations
- 🇸🇪
Department of Prosthetic Dentistry, Malmö University, Malmö, Sweden